Skip to content

Anagenex vs Orbis Medicines

Anagenex logo

Anagenex

Evolving new small molecule medicines by combining ultra high throughput biochemistry and machine learning

5 employees · est. 2019 · Lexington, United States

VS
Orbis Medicines logo

Orbis Medicines

Reshaping the future of drug discovery

47 employees · est. 2021 · Denmark

Anagenex is the older company (2019 vs 2021); Orbis Medicines is the larger of the two.

Side-by-Side Comparison

Anagenex Orbis Medicines
Founded
2019 older 2021
Headquarters
Lexington, United States Denmark
Employees
5 47 larger
Funding Stage
Series A Series A
Total Funding
$37.20M $116.00M
Funding Rounds
4 4
Services
Online Casino Platform, Live Casino Games, Sports Betting, Mobile Application Development of oral macrocycle drug candidates, Exploration and optimization of macrocycle chemical space, Integration of AI and large-scale data for drug discovery, Collaborative research and licensing agreements
Target Customers
Online Gamblers, Sports Betting Enthusiasts, Cryptocurrency Users, Mobile Gamers Healthcare Providers, Pharmaceutical Companies, Biotechnology Researchers, Patients requiring biologic drug alternatives
Taxonomy
Small Molecule MedicinesUltra High Throughput BiochemistryDrug DiscoverySeed StageNovel PlatformDifficult Targets +4 Drug DiscoveryMacrocyclic ChemistryComputational PlatformHigh-throughput ScreeningChallenging TargetsPharmaceutical Innovation +6
Website
anagenex.com orbismedicines.com
Anagenex logo

About Anagenex

Anagenex, founded in 2019 and headquartered in the United States, is making waves in pharmaceutical innovation by merging ultra high throughput biochemistry with machine learning. With its slogan, "Evolving new small molecule medicines by combining ultra high throughput biochemistry and machine lear...

Orbis Medicines logo

About Orbis Medicines

Orbis Medicines, founded in 2021, is at the forefront of transforming drug discovery. With the slogan "Reshaping the future of drug discovery," the company is dedicated to developing a comprehensive platform designed to discover, develop, and deliver drug candidates targeting challenging medical con...

Also comparing in this category

Comparing more than these two?

Get Anagenex, Orbis Medicines and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Anagenex compare?

A PDF of Anagenex and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Anagenex was founded in 2019, based in Lexington, United States, with 5 employees. Anagenex, founded in 2019 and headquartered in the United States, is making waves in pharmaceutical innovation by merging ultra high throughput biochemistry with machine learning. With its slogan, "Ev. Orbis Medicines was founded in 2021, based in Denmark, with 47 employees. Orbis Medicines, founded in 2021, is at the forefront of transforming drug discovery. With the slogan "Reshaping the future of drug discovery," the company is dedicated to developing a comprehensive p.
Anagenex has raised $37.20M and Orbis Medicines $116.00M. Latest stage: Anagenex Series A, Orbis Medicines Series A.
Both list drug discovery and pharmaceutical innovation among their focus areas.

Compare Anagenex with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Anagenex on 15 Jun 2026, and Orbis Medicines on 21 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout